Clinical Trial Update: Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating Zemplar Capsule (paricalcitol) shows safety and efficacy in reducing serum intact parathyroid hormone in adults with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Zemplar Capsule (paricalcitol)

Snippet

Sponsor: Abbott | Conditions: Renal Insufficiency, Chronic | Phase 3 | Status: COMPLETED